ClinicalTrials.gg
CompletedNCT05544734Updated Sep 28, 2023Results posted

Hydrocodone Compared to Acetaminophen and Ibuprofen for Post-nail Procedure Analgesia

A Phase 4 interventional study of Hydrocodone 5Mg/Acetaminophen 325Mg Tab and Acetaminophen 1000mg in Nail Diseases and Nail Abnormality, sponsored by Weill Medical College of Cornell University. Completed at 1 site in United States. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by Weill Medical College of Cornell University · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 95 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety and efficacy of ropivacaine and hydrocodone for nail-procedure associated pain management. The investigators hypothesize that ropivacaine with hydrocodone will be superior to ropivacaine with acetaminophen and ibuprofen for managing pain.

02

Conditions studied

  • Nail Diseases
  • Nail Abnormality

Keywords

  • nail diseases
  • nail biopsy
  • nail procedure
  • pain management
03

In context

Lead sponsor

Weill Medical College of Cornell University is the lead sponsor of 892 studies on the registry; 165 are open to participants now.

Of its 123 completed or terminated interventional studies of FDA-regulated products, 94 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing fingernail or toenail, excision, or shave
  • Must understand and voluntarily sign an form
  • Must be male or female and aged 18-95 years at time of consent
  • Must be able to adhere to the study visit schedule and other protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Subject is unable to provide written for any reason
  • Subject has peripheral vascular disease, arterial insufficiency, peripheral neuropathy
  • Subject is on Aspirin, NSAIDs, or consumes a chronic medication for control of any other chronic pain
  • Subject has a history of opioid or alcohol use disorder
  • Subject has a history of peptic ulcer disease, gastritis, chronic renal insufficiency or a history of kidney disease, or has underlying liver disease
  • Subject has a history of severe constipation
  • Subject is sensitive or allergic to any of the elements included in this study
  • Subject is unable to complete the required pain dairy
  • Subject is pregnant, planning pregnancy, or nursing
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Hydrocodone 5mg/acetaminophen 325mg

    Participants receive oral hydrocodone 5 mg/acetaminophen 325 mg every 4 hours for 2 days, followed by oral acetaminophen 1000 mg and oral ibuprofen 400 mg every 6 hours for 4 days

    Drug: Hydrocodone 5Mg/Acetaminophen 325Mg Tab · Drug: Acetaminophen 1000mg · Drug: Ibuprofen 400 mg

  • Active comparator
    Acetaminophen 1000mg + Ibuprofen 400mg

    Participants receive oral acetaminophen 1000 mg and oral ibuprofen 400 mg every 6 hours for 6 days

    Drug: Acetaminophen 1000mg · Drug: Ibuprofen 400 mg

Interventions

  • DrugHydrocodone 5Mg/Acetaminophen 325Mg Tab

    Drug page: Hydrocodone

    5 mg/325 mg tablet

    Also known as: Vicodin, Norco, Lortab

  • 1000 mg tablet

    Also known as: Tylenol

  • 400 mg tablet

    Also known as: Advil, Motrin

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Pain Scores on Postoperative Day 2, as Measured by the Wong-Baker 0-to-10 Pain Scale

    Change in pain scores obtained with the Wong-Baker 0-to-10 pain scale between the 2 groups on postoperative day 2. The Wong-Baker 0-to-10 pain scale is used for rating the severity of pain, with scores ranging from 0 to 10, and higher scores indicating greater severity of pain.

    Time frame: Baseline, 2 days

Secondary outcomes

  1. Change in Health-related Quality of Life Scores on Postoperative Days 3 and 6, as Measured by an Adapted APS-POQ-R Questionnaire

    Change in health-related quality of life associated with pain obtained with an adapted version of the APS-POQ-R (APS Patient Outcome Questionnaire) between the 2 groups on postoperative days 3 and 6. The APS-POQ-R is a questionnaire used for rating health-related quality of life associated with pain, with scores of each domain ranging from 0 to 10 or 0% to 100%, and higher scores indicating greater severity of impact on quality of life (12 domains summed up for total score range of minimum 0 to maximum 120).

    Time frame: 3 days, 6 days (end of study)

07

Results

Posted Sep 28, 2023

Participant flow

Participant flow — Overall Study
MilestoneHydrocodone 5mg/Acetaminophen 325mgAcetaminophen 1000mg + Ibuprofen 400mg
Started1010
Completed1010
Not completed00

Outcome measures

PrimaryChange From Baseline in Pain Scores on Postoperative Day 2, as Measured by the Wong-Baker 0-to-10 Pain Scale

Change in pain scores obtained with the Wong-Baker 0-to-10 pain scale between the 2 groups on postoperative day 2. The Wong-Baker 0-to-10 pain scale is used for rating the severity of pain, with scores ranging from 0 to 10, and higher scores indicating greater severity of pain.

Time frame:
Baseline, 2 days
Reported as:
Mean · score on a scale
Change From Baseline in Pain Scores on Postoperative Day 2, as Measured by the Wong-Baker 0-to-10 Pain Scale
score on a scaleHydrocodone 5mg/Acetaminophen 325mgAcetaminophen 1000mg + Ibuprofen 400mg
Change From Baseline in Pain Scores on Postoperative Day 2, as Measured by the Wong-Baker 0-to-10 Pain Scale2.1 ± 1.62.4 ± 1.7
Statistical analysis
  • Hydrocodone 5mg/Acetaminophen 325mg vs Acetaminophen 1000mg + Ibuprofen 400mg · t-test, 2 sided · p = 0.69 · Median difference (final values): -0.30 · 95% CI -1.85 to 1.25Direction = Hydrocodone group mean change (i.e., change = baseline to postoperative day 2) minus Non-Hydrocodone group mean change (i.e., change = baseline to postoperative day 2).
SecondaryChange in Health-related Quality of Life Scores on Postoperative Days 3 and 6, as Measured by an Adapted APS-POQ-R Questionnaire

Change in health-related quality of life associated with pain obtained with an adapted version of the APS-POQ-R (APS Patient Outcome Questionnaire) between the 2 groups on postoperative days 3 and 6. The APS-POQ-R is a questionnaire used for rating health-related quality of life associated with pain, with scores of each domain ranging from 0 to 10 or 0% to 100%, and higher scores indicating greater severity of impact on quality of life (12 domains summed up for total score range of minimum 0 to maximum 120).

Time frame:
3 days, 6 days (end of study)
Reported as:
Mean · score on a scale
Change in Health-related Quality of Life Scores on Postoperative Days 3 and 6, as Measured by an Adapted APS-POQ-R Questionnaire
score on a scaleHydrocodone 5mg/Acetaminophen 325mgAcetaminophen 1000mg + Ibuprofen 400mg
Change in Health-related Quality of Life Scores on Postoperative Days 3 and 6, as Measured by an Adapted APS-POQ-R Questionnaire12.7 ± 11.210.4 ± 9.0
Statistical analysis
  • Hydrocodone 5mg/Acetaminophen 325mg vs Acetaminophen 1000mg + Ibuprofen 400mg · t-test, 2 sided · p = 0.62 · Median difference (final values): 2.30 · 95% CI -7.25 to 11.85Direction = Hydrocodone group mean change (i.e., change = postoperative day 3 to postoperative day 6) minus Non-Hydrocodone group mean change (i.e., change = postoperative day 3 to postoperative day 6).

Adverse events

Collected over 30 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Hydrocodone 5mg/Acetaminophen 325mg0/10 (0%)0/10 (0%)0/10 (0%)
Acetaminophen 1000mg + Ibuprofen 400mg0/10 (0%)0/10 (0%)0/10 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Hydrocodone 5mg/Acetaminophen 325mgAcetaminophen 1000mg + Ibuprofen 400mgTotal
<=18 years000
Between 18 and 65 years6713
>=65 years437
Age, Continuous
Age, Continuous(years)Hydrocodone 5mg/Acetaminophen 325mgAcetaminophen 1000mg + Ibuprofen 400mgTotal
Mean53.3 (22 to 84)47.7 (23 to 69)50.5 (22 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)Hydrocodone 5mg/Acetaminophen 325mgAcetaminophen 1000mg + Ibuprofen 400mgTotal
Female6612
Male448
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Hydrocodone 5mg/Acetaminophen 325mgAcetaminophen 1000mg + Ibuprofen 400mgTotal
Hispanic or Latino336
Not Hispanic or Latino7714
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Hydrocodone 5mg/Acetaminophen 325mgAcetaminophen 1000mg + Ibuprofen 400mgTotal
American Indian or Alaska Native000
Asian224
Native Hawaiian or Other Pacific Islander000
Black or African American123
White7613
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Hydrocodone 5mg/Acetaminophen 325mgAcetaminophen 1000mg + Ibuprofen 400mgTotal
United States101020
08

Study locations

1 site
  • Weill Medical College of Cornell University
    New York, New York 10021, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in May 2023, 6 months.

Results were first posted in Sep 2023, 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2022
First posted
Sep 16, 2022
StartActual
Nov 10, 2022
Primary completionActual
May 15, 2023
CompletionActual
Jun 1, 2023
Results first posted
Sep 28, 2023
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05544734
Responsible party
Sponsor
First posted
Sep 16, 2022
Start date
Nov 10, 2022
Primary completion
May 15, 2023
Completion
Jun 1, 2023
Results posted
Sep 28, 2023
Last update
Sep 28, 2023

Study contacts

Shari Lipner, MD, PhD
principal investigator · Weill Medical College of Cornell University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydrocodone

Start the discussion